Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
Synaffix to provide access to proprietary Antibody-Drug…
Sequana Medical announces grant of additional DSR® patent in United States
Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext…
Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer
Dr. Gericke brings extensive experience in the research and…
ViCentra bolsters leadership team with the appointment of Leo Toole as Chief Financial Officer and expands European commercialization
Newly appointed CFO with significant experience in medical…
Neuraxpharm announces closing of acquisition of established products from Sanofi
Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm…
Pre-launch of MED3000 Eroxon™ ahead of H1 2023 launch
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Destiny Pharma plc – US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections
Brighton, United Kingdom – 25 January 2023 – Destiny Pharma…
STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference
Data demonstrates that STC-15, an oral METTL3 inhibitor,…
2022 Novo Holdings Seed Investments team Re-view/Business Update
Two successful exits – Syndesi and BioPhero
Four portfolio…
Neuraxpharm completes its presence in the Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg
Belgium team to expand under Country Manager, Dr Pierre-Hervé…
NeoPhore completes extension to Series B financing to further advance discovery pipeline
Scientific milestones achieved significantly ahead of schedule
Cambridge,…
Poolbeg announces strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and…
STORM Therapeutics Expands R&D Leadership Team
Matthew Fyfe joins as Senior Vice President of Therapeutics
…
Novo Holdings participates in portfolio company Amolyt Pharma’s $138 million financing
Amolyt is developing therapeutic peptides for rare endocrine…
Novo Holdings invests in proteomics technology company, Evosep
COPENHAGEN, DENMARK — Novo Holdings, a leading international…
Positive Initial Data Analysis in POLB 001 LPS Challenge Trial
Early data read out indicates a successful LPS human challenge…
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V.,…
IOnctura Provides Development Update On First-In-Class Semi-Allosteric PI3Kδ Inhibitor Program
Updated clinical data demonstrates a prolonged and sustained…
MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
Newly appointed CMO with more than 25 years’ experience…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York